New cocktail aims to beat back lymphoma when other treatments fail

NCT ID NCT06563596

Recruiting now Disease control Sponsor: Reid Merryman, MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in 45 people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo shrinks tumors and how safe it is. Participants must have had at least one prior therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: epcoritamab, zanubrutinib, and rituximab
What this could lead to: If successful, this combination could offer a new, effective treatment option for people with relapsed or refractory follicular or marginal zone lymphoma, potentially improving remission rates.
What could go wrong: This is a small, early-phase (phase 2) trial with only 45 participants. The combination may not work as hoped, and side effects from the three drugs could be significant. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA LYMPHOMA MARGINAL ZONE LYMPHOMA NON-HODGKIN LYMPHOMA REFRACTORY LYMPHOMA RELAPSED LYMPHOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
The Ohio State University Wexner Medical Center
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.